A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis

This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.

NCT Number	NCT07684157
Lead Sponsor	Jacobio Pharmaceuticals Co., Ltd.
Conditions	Rheumatoid Arthritis (RA)
Enrollment	32 participants
Start Date	2026-07-29
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-06